# TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study

> **NCT02252354** · PHASE1 · COMPLETED · sponsor: **Takeda** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** [14C]-TAK-385 Oral Solution
- **DRUG:** TAK-385 Tablets
- **DRUG:** [14C]-TAK-385 Solution for Intravenous Infusion

## Key facts

- **NCT ID:** NCT02252354
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2014-10
- **Final completion:** 2014-10
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2016-10-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02252354

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02252354, "TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02252354. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*